The Aptamarker platform’s capacity to apply the same 16.8 million sequences to various samples, including biological fluids, cells, or tissue on slides, represents a powerful tool for identifying variation in protein abundance across different phenotypes. This can be done with a single Next-Generation Sequencing (NGS) analysis to characterize all aptamer-target complexes.

The Aptamarker platform can achieve everything that is possible with other next-generation proteomics platforms and more. The depth of our system allows for multiple Aptamarkers binding to the same protein, thus enabling direct epitope mapping. By enabling epitope characterization, the platform extends analysis beyond canonical reference proteins to the forms of proteins actually found in vivo in a disease state. This includes complexes, isoforms, cleavage events, post-translational modifications, and foldings.

We are currently working to develop the knowledge base necessary to identify all proteins in the human proteome. This will be possible with a single Aptamarker library, and a single NGS analysis per sample.